was founded in 2000 by randy scott who had previously founded and been ceo at incyte he formed the company after a close friend was diagnosed with cancer and had the idea for treatment based on the specific genome of their tumor by 2003 genomic health had developed oncotype dx a genomic assay that quantified the likelihood of breast cancer recurrence this development took the company over three years and to complete and then had to convince skeptics at the time of the validity of genetic testing in july 2005 genomic health filed for an initial public offering to sell up to in common stock investors at the time already included versant ventures and kleiner perkins caufield byers on it was listed on the nasdaq with the symbol ghdx with the initial share price of for 5016722 shares genomic health also started a subsidiary in 2010 invitae with the goal of aggregating multiple genetics tests the company expanded with international headquarters in geneva switzerland and uk headquarters in london in 2011 in july 2019 exact sciences announced that it was purchasing genomic health to increase the variety of medical tests they offer